News
Your Sample Can Change the Future of Neuroendocrine Cancer Care
By Anna Greene, PhD, NETRF Chief Scientific Officer Neuroendocrine cancers, such as neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs), are rare and complex. That makes
AlphaMedix™ Shows Promising Phase 2 Results in Advanced Neuroendocrine Tumors
Updated on October 31, 2025 Early clinical trial results show that AlphaMedix™ (212Pb-DOTAMTATE), an investigational targeted alpha therapy, achieved all of its main goals and
Embracing the ‘Just Be’ Lifestyle: A Conversation with Burt Rosen
By Anne-Marie Green, Director of Digital Communications We recently spoke with Burt Rosen, who was diagnosed with both an advanced PNET (Pancreatic Neuroendocrine Tumor) and
Make Your Voice Heard: Share Your Experience with NET/NEC Care
This is your opportunity to be part of a global effort to improve neuroendocrine cancer care. The 2nd Survey of Challenges in Access to Diagnostics and Treatment for
Charting the Future of Neuroendocrine Cancer Research: The NETRF Research Roadmap
At the Neuroendocrine Tumor Research Foundation (NETRF), we are dedicated to transforming the future of neuroendocrine cancer care. As the world’s leading funder of neuroendocrine
Sharing Knowledge, Driving Change: Highlights from the INCA Summit
By Elyse Gellerman, CEO Representatives from 25 neuroendocrine cancer advocacy groups gathered earlier this month in Sofia, Bulgaria, for the 13th INCA (International Neuroendocrine Cancer
Neuroendocrine Cancer on the Rise: What the Latest Research Shows
By Anna Greene, PhD, NETRF Director of Research A major new study published in JAMA Network Open by Arvind Dasari, MD, MS, and colleagues provides
A New Consensus: Shedding Light on NET G3 Care
By Anna Greene, PhD, NETRF Director of Research We’re excited to share insights from a new ENETS (European Neuroendocrine Tumor Society) position statement, published in
NETRF Fosters Learning and Community in Birmingham
By Anne-Marie Green, NETRF Director of Digital Communications NETRF brought the NET Impact Thrivership & Research Education Program to Alabama for the first time on
A New Genetic Clue to Aggressive Pancreatic Neuroendocrine Tumors
By Anna Greene, PhD, NETRF Director of Research Pancreatic neuroendocrine tumors (PanNETs) are rare and tricky. Some grow slowly and never cause trouble, while others